Janssen has announced that Health Canada has approved Simponi (golimumab) for the treatment of moderately to severely active ulcerative colitis (UC). Simponi is the first and only subcutaneously administered anti-tumor necrosis factor-alfa therapy approved in Canada to reduce signs and symptoms, induce clinical remission, achieve sustained clinical remission in induction responders and improve endoscopic appearance of the mucosa during induction in adult patients with moderately to severely active UC who have had an inadequate response to conventional therapy. For more details, go to: http://www.newswire.ca/en/story/1230187/simponi-r-golimumab-receives-health-canada-approval-for-ulce...